Have a feature idea you'd love to see implemented?
Let us know!
BNGO Bionano Genomics Inc
Price (delayed)
$0.2191
Market cap
$22.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.32
Enterprise value
$36.01M
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for
Highlights
The EPS has soared by 67% YoY and by 54% QoQ
The company's net income rose by 40% YoY and by 33% QoQ
Bionano Genomics's debt has soared by 121% YoY but it has decreased by 19% from the previous quarter
Bionano Genomics's gross profit has plunged by 107% YoY and by 106% from the previous quarter
BNGO's gross margin has dropped by 107% year-on-year and by 106% since the previous quarter
Key stats
What are the main financial stats of BNGO
Market
Valuations
Earnings
Shares outstanding
101.99M
Market cap
$22.35M
Enterprise value
$36.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.39
Price to sales (P/S)
0.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.08
Revenue
$33.33M
EBIT
-$130.77M
EBITDA
-$115.33M
Free cash flow
-$93.05M
Per share
Balance sheet
Liquidity
EPS
-$2.32
Free cash flow per share
-$1.08
Book value per share
$0.57
Revenue per share
$0.39
TBVPS
$0.89
Total assets
$87.36M
Total liabilities
$38.49M
Debt
$22.45M
Equity
$48.87M
Working capital
$14.03M
Debt to equity
0.46
Current ratio
1.43
Quick ratio
0.86
Net debt/EBITDA
-0.12
Margins
Efficiency
Dividend
EBITDA margin
-346%
Gross margin
-1.8%
Net margin
-407.3%
Operating margin
-340.6%
Return on assets
-92.2%
Return on equity
-176.3%
Return on invested capital
-146.7%
Return on capital employed
-240.3%
Return on sales
-392.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BNGO stock price
How has the Bionano Genomics stock price performed over time
Intraday
4.63%
1 week
-14.38%
1 month
-31.64%
1 year
-84.89%
YTD
-88.41%
QTD
-51.73%
Financial performance
How have Bionano Genomics's revenue and profit performed over time
Revenue
$33.33M
Gross profit
-$599,000
Operating income
-$113.55M
Net income
-$135.78M
Gross margin
-1.8%
Net margin
-407.3%
Bionano Genomics's gross profit has plunged by 107% YoY and by 106% from the previous quarter
BNGO's gross margin has dropped by 107% year-on-year and by 106% since the previous quarter
The operating margin has increased by 50% year-on-year and by 32% since the previous quarter
BNGO's operating income has soared by 50% YoY and by 38% from the previous quarter
Growth
What is Bionano Genomics's growth rate over time
Valuation
What is Bionano Genomics stock price valuation
P/E
N/A
P/B
0.39
P/S
0.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.08
The EPS has soared by 67% YoY and by 54% QoQ
BNGO's price to book (P/B) is 89% lower than its 5-year quarterly average of 3.6 and 44% lower than its last 4 quarters average of 0.7
BNGO's equity has plunged by 59% YoY and by 39% from the previous quarter
The P/S is 98% below the 5-year quarterly average of 33.7 and 60% below the last 4 quarters average of 1.4
Bionano Genomics's revenue has decreased by 9% QoQ
Efficiency
How efficient is Bionano Genomics business performance
Bionano Genomics's return on equity has shrunk by 58% YoY but it has increased by 18% QoQ
The ROS has increased by 41% YoY and by 28% QoQ
Bionano Genomics's ROIC has increased by 30% from the previous quarter and by 18% YoY
Bionano Genomics's return on assets has increased by 23% QoQ but it has decreased by 7% YoY
Dividends
What is BNGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BNGO.
Financial health
How did Bionano Genomics financials performed over time
BNGO's total assets is 127% greater than its total liabilities
BNGO's total assets has dropped by 52% year-on-year and by 32% since the previous quarter
BNGO's quick ratio has dropped by 52% year-on-year and by 11% since the previous quarter
Bionano Genomics's debt is 54% less than its equity
Bionano Genomics's debt has soared by 121% YoY but it has decreased by 19% from the previous quarter
BNGO's equity has plunged by 59% YoY and by 39% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.